Two New Analyses Reinforce Consistent Efficacy of Novartis Pharmaceuticals Corporation Therapy Gilenya Across Wide Range of Relapsing MS Patients

East Hanover, NJ, May 31, 2012 A new post-hoc analysis of data from the FREEDOMS study demonstrated that the efficacy of Gilenya (fingolimod) in patients with relapsing-remitting multiple sclerosis (…
Read the full story: BioSpace.com Featured News